<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127749</url>
  </required_header>
  <id_info>
    <org_study_id>NL45198.018.13</org_study_id>
    <secondary_id>NL45198.018.13</secondary_id>
    <nct_id>NCT02127749</nct_id>
  </id_info>
  <brief_title>The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia</brief_title>
  <acronym>MISSION-2</acronym>
  <official_title>The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with antibiotics, which harm the&#xD;
      gut flora, causes the immune system to be less effective.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Sepsis ranks among the top ten leading causes of death worldwide. Most&#xD;
      nonsurvivors die in a state of immunosuppression. The gut microbiota exerts numerous&#xD;
      beneficial functions in the host response against infections. Gut flora components express&#xD;
      microorganism-associated molecular patterns (MAMPs) such as lipopolysaccharide (LPS), which&#xD;
      are recognized by pattern recognition receptors (PRRs) expressed by neutrophils and&#xD;
      macrophages. MAMPs from the intestinal microbiota constitutively translocate to the&#xD;
      circulation and prime bone marrow derived neutrophils via PRRs. Antibiotic treatment, which&#xD;
      is standard of care for all patients with sepsis, depletes the gut microbiota and leads to a&#xD;
      diminished release of MAMPs and other bacteria derived products. This causes diminished&#xD;
      priming of systemic immunity, which may attribute to sepsis associated immunosuppression and&#xD;
      an increased susceptibility to invading bacteria.&#xD;
&#xD;
      Objective: To investigate the role of the gut microbiota in the systemic priming of immune&#xD;
      effector cells during human endotoxemia&#xD;
&#xD;
      Study design: Randomized, between- and within-subject-controlled intervention study in human&#xD;
      volunteers&#xD;
&#xD;
      Intervention: All subjects will receive lipopolysaccharide (endotoxin; 2 ng/kg bodyweight)&#xD;
      intravenously to induce experimental endotoxemia. Eight subjects will be pretreated with&#xD;
      broad spectrum antibiotics (ciprofloxacin, vancomycin, metronidazole) for seven days (washout&#xD;
      period of 36 hours before endotoxemia), in order to deplete the gut microbiota. Blood and&#xD;
      faeces will be sampled before, during and after endotoxemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine production in blood</measure>
    <time_frame>within 8 hours after LPS administration</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Endotoxemia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are not pretreated with antibiotics Subjects receive 2 ng/kg endotoxin intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are pretreated with broad-spectrum antibiotics: Vancomycin, Metronidazole, Ciprofloxacin Subjects receive 2 ng/kg endotoxin intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endotoxin</intervention_name>
    <description>Both groups will receive 2 ng/kg LPS (endotoxin) intravenously</description>
    <arm_group_label>Antibiotics</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>LPS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin, Metronidazole, Ciprofloxacin</intervention_name>
    <description>ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days</description>
    <arm_group_label>Antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Male between 18 and 35 years of age&#xD;
&#xD;
          -  Capable of giving written informed consent&#xD;
&#xD;
          -  Chemistry panel without any clinically relevant abnormality&#xD;
&#xD;
          -  Normal defecation pattern&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major illness in the past 3 months or any chronic medical illness&#xD;
&#xD;
          -  History of any type of malignancy&#xD;
&#xD;
          -  Past or current gastrointestinal disease&#xD;
&#xD;
          -  Known positive test for hepatitis C antibody, hepatitis B surface antigen or HIV&#xD;
             antibody 1 or 2&#xD;
&#xD;
          -  Current or chronic history of liver disease&#xD;
&#xD;
          -  Subject uses tobacco products&#xD;
&#xD;
          -  History, within 3 years, of drug abuse&#xD;
&#xD;
          -  History of alcoholism&#xD;
&#xD;
          -  Any clinically relevant abnormality on the 12-lead ECG&#xD;
&#xD;
          -  The subject has received an investigational product within three months&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs&#xD;
&#xD;
          -  Use of antibiotics within 12 months&#xD;
&#xD;
          -  Known allergy to antibiotics&#xD;
&#xD;
          -  Subject has difficultly in donating blood or accessibility of a vein in left or right&#xD;
             arm.&#xD;
&#xD;
          -  Subject has donated more than 350 mL of blood in last 3 months&#xD;
&#xD;
          -  Difficulty swallowing pills&#xD;
&#xD;
          -  Body mass index more than 28&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. J. Wiersinga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Centre, Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>W.J. Wiersinga, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>antibiotics</keyword>
  <keyword>gut microbiota</keyword>
  <keyword>endotoxemia</keyword>
  <keyword>innate immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endotoxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

